Exact Sciences Co. (NASDAQ:EXAS) Shares Purchased by Kestra Private Wealth Services LLC

Kestra Private Wealth Services LLC lifted its position in Exact Sciences Co. (NASDAQ:EXAS) by 5.3% during the fourth quarter, Holdings Channel reports. The institutional investor owned 5,216 shares of the medical research company’s stock after buying an additional 264 shares during the quarter. Kestra Private Wealth Services LLC’s holdings in Exact Sciences were worth $386,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the business. Jennison Associates LLC lifted its holdings in shares of Exact Sciences by 94.0% in the fourth quarter. Jennison Associates LLC now owns 1,360,917 shares of the medical research company’s stock valued at $100,681,000 after purchasing an additional 659,235 shares in the last quarter. Artisan Partners Limited Partnership boosted its position in shares of Exact Sciences by 11.8% in the third quarter. Artisan Partners Limited Partnership now owns 3,961,514 shares of the medical research company’s stock valued at $270,254,000 after acquiring an additional 418,770 shares during the period. Qube Research & Technologies Ltd grew its stake in shares of Exact Sciences by 328.3% in the third quarter. Qube Research & Technologies Ltd now owns 540,191 shares of the medical research company’s stock worth $36,852,000 after acquiring an additional 414,059 shares during the last quarter. Victory Capital Management Inc. grew its stake in shares of Exact Sciences by 230.8% in the third quarter. Victory Capital Management Inc. now owns 510,388 shares of the medical research company’s stock worth $34,819,000 after acquiring an additional 356,084 shares during the last quarter. Finally, Armistice Capital LLC increased its position in Exact Sciences by 50.7% during the third quarter. Armistice Capital LLC now owns 711,520 shares of the medical research company’s stock worth $48,540,000 after acquiring an additional 239,520 shares during the period. 88.82% of the stock is currently owned by institutional investors.

Exact Sciences Stock Down 3.1 %

Shares of NASDAQ EXAS opened at $61.41 on Wednesday. Exact Sciences Co. has a 52-week low of $56.05 and a 52-week high of $100.77. The company has a debt-to-equity ratio of 0.74, a quick ratio of 2.07 and a current ratio of 2.32. The business has a fifty day moving average of $63.58 and a two-hundred day moving average of $64.69. The stock has a market cap of $11.29 billion, a PE ratio of -53.87 and a beta of 1.26.

Exact Sciences (NASDAQ:EXAS) last announced its quarterly earnings results on Wednesday, February 21st. The medical research company reported ($0.27) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.53) by $0.26. The firm had revenue of $646.89 million during the quarter, compared to the consensus estimate of $638.83 million. Exact Sciences had a negative net margin of 8.17% and a negative return on equity of 6.60%. The firm’s quarterly revenue was up 17.0% on a year-over-year basis. During the same period last year, the firm posted ($0.72) EPS. As a group, equities research analysts expect that Exact Sciences Co. will post -0.86 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on EXAS shares. William Blair reissued an “outperform” rating on shares of Exact Sciences in a report on Thursday, February 22nd. Canaccord Genuity Group decreased their target price on Exact Sciences from $100.00 to $90.00 and set a “buy” rating on the stock in a research report on Thursday, February 22nd. TheStreet cut Exact Sciences from a “c-” rating to a “d+” rating in a report on Monday, February 26th. Finally, Citigroup reiterated a “buy” rating and issued a $100.00 price objective on shares of Exact Sciences in a research report on Wednesday, April 3rd. Two equities research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $99.07.

Insiders Place Their Bets

In other news, General Counsel James Herriott sold 415 shares of the company’s stock in a transaction that occurred on Wednesday, February 21st. The shares were sold at an average price of $61.50, for a total transaction of $25,522.50. Following the transaction, the general counsel now directly owns 6,943 shares in the company, valued at $426,994.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In related news, EVP Sarah Condella sold 2,000 shares of the firm’s stock in a transaction dated Thursday, March 28th. The stock was sold at an average price of $70.00, for a total value of $140,000.00. Following the transaction, the executive vice president now owns 73,787 shares in the company, valued at $5,165,090. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, General Counsel James Herriott sold 415 shares of Exact Sciences stock in a transaction that occurred on Wednesday, February 21st. The stock was sold at an average price of $61.50, for a total transaction of $25,522.50. Following the sale, the general counsel now owns 6,943 shares of the company’s stock, valued at approximately $426,994.50. The disclosure for this sale can be found here. Insiders have sold a total of 70,611 shares of company stock valued at $4,255,377 in the last 90 days. 1.30% of the stock is currently owned by insiders.

Exact Sciences Company Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.